There are currently 127 active clinical trials seeking participants for Major Depressive Disorder research studies. The states with the highest number of trials for Major Depressive Disorder participants are California, Florida, Texas and New York.
Individualized (fMRI-guided) TMS Treatment for Depression
NCT06266390
Recruiting
The purpose of this study is to investigate the responses of the brain region known as the subgenual anterior cingulate cortex (sgACC) during transcranial magnetic stimulation (TMS) in individuals with depression. Specifically, investigators aim to determine whether the sgACC is engaged when TMS is delivered to specific targets and if the engagement of sgACC changes throughout a full TMS treatment intervention. To achieve this goal, the investigators will employ a combination of TMS and Magnetic... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/21/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Depression, Major Depressive Disorder, Persistent Depressive Disorder
Register for Updates
Study of ALTO-300 in MDD
NCT05922878
Recruiting
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/21/2025
Locations: Site 200, Phoenix, Arizona +44 locations
Conditions: Major Depressive Disorder
Register for Updates
Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression
NCT06480201
Recruiting
The core objective of this study is to enhance the translational potential of this electroencephalogram (EEG) biomarker by using ketamine(KET)-induced gamma potentiation as a prognostic marker of 4-week treatment outcome. Previous research focused exclusively on KET-induced gamma band potentiation (GBP) in the context of a single infusion. Our study design captures the clinical variation associated with real-world treatment resistant depression (TRD) patients and allows us to analyze the relativ... Read More
Gender:
ALL
Ages:
Between 21 years and 45 years
Trial Updated:
07/17/2025
Locations: Wells Medicine, Houston, Texas +1 locations
Conditions: Healthy, Major Depressive Disorder, Treatment Resistant Depression
Register for Updates
Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression
NCT06419608
Recruiting
The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/14/2025
Locations: Reverie Mind, LLC, Chandler, Arizona +66 locations
Conditions: Major Depressive Disorder
Register for Updates
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
NCT06058039
Recruiting
This randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 35 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and mee... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/11/2025
Locations: Neumora Investigator Site, Cerritos, California +68 locations
Conditions: Major Depressive Disorder
Register for Updates
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
NCT06058013
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/11/2025
Locations: Neumora Investigator Site, Encino, California +70 locations
Conditions: Major Depressive Disorder
Register for Updates
Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression
NCT06559826
Recruiting
The proposed study is a single-site, randomized, controlled clinical trial (RCT) comparing ketamine-assisted psychotherapy (KAP) to a standard evidence-based regimen of ketamine administered in a medical model without psychotherapy (KET). Eligible study participants will be adults with major depressive disorder (MDD). Adults with MDD will be randomized to KAP or KET in a 1:1 allocation. Each treatment group will receive KAP or KET over a period of four weeks. Measurement of depression severity,... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
07/10/2025
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Major Depressive Disorder
Register for Updates
Imaging Depression in Parkinson's Disease
NCT06402955
Recruiting
The goal of this observational study is to identify targetable neural substrates of depression in Parkinson's Disease for the first time in people with Parkinson's between the ages of 40 and 80, who are experiencing symptoms of depression.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
07/09/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Parkinson's Disease, Major Depressive Disorder
Register for Updates
Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents
NCT05437588
Recruiting
This study is dedicated to help identify biomarkers for depression and suicide. The purpose of the study is to better understand these links to improve medical and psychiatric care in the future. This research is also to test the effects of standard treatment of depression on improvement in depressive and suicidal behavior and on biomarkers (e.g. miRNA) for these disorders.
Gender:
ALL
Ages:
Between 10 years and 24 years
Trial Updated:
07/08/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +1 locations
Conditions: Major Depressive Disorder, Suicidal Ideas, Suicide, Attempted, MDD, Depression, Depression, Teen, Depression and Suicide, Depression in Adolescence, Suicide
Register for Updates
Mood Effects of Serotonin Agonists: Depression
NCT07017478
Recruiting
This study will examine the effect of a low dose of the 5HT2A agonist LSD (26 µg), compared to placebo, on acute and protracted mood states in individuals with depression. The investigators will assess the relationship between mood-related symptoms and EEG as a neurophysiological marker.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
07/01/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: LSD, Major Depressive Disorder, Depression
Register for Updates
Neural Circuit Effects of Ketamine in Depression
NCT06213324
Recruiting
This project is designed to examine the role of the subgenual anterior cingulate cortex (sgACC) in anhedonia and anxiety in humans with depression, as well as the acute and sustained effects of ketamine on agACC activation and depression symptoms.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/30/2025
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Major Depressive Disorder
Register for Updates
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
NCT05850689
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/30/2025
Locations: Clinical Site, Huntsville, Alabama +59 locations
Conditions: Major Depressive Disorder
Register for Updates